News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Egetis in the media

Redeye research, April 30, 2020

Egetis: Aladote upside

World of Gastrointestinal Oncology, Feb 17 2020

Neuropathy experienced by colorectal cancer patients receiving oxaliplatin

Interview with Mr Akschuti, analyst at Pareto Securities, Feb 6 2020

Pareto Securities equity analyst elaborates on the US clinical hold for the POLAR-M study.

Läkemedelsvärlden, December 14, 2020 (in Swedish)

Increasing number of cases with acetaminophen overdose in Sweden.

The independent financial news site EFN, Dec 9 2019

Egetis mentioned on EFN as one of the Swedish healthcare companies to keep an eye on. The discussion in English starts 5 min 30 sec into the program.

Liver Research

“Thus, if efficacy in high overdose patients can be established, calmangafodipir may be a promising complementary antidote to NAC.” Oct 2019

Jaeschke H, Duan L, Nguyen N, Ramachandran A, Mitochondrial damage and biogenesis in acetaminophen-induced liver injury, Liver Research

Svd Näringsliv 19 januari 2019 (in Swedish)

Egetis: Håller nerverna i styr genom studietider
Keeps their nerves in control through the study

Calendar and upcoming reports

August 19, 2021
Interim report April-June

September 1-2, 2021
Pareto healthcare conference

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com